Remove Communication Remove Insurance Coverage and Processing Remove Packaging
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

The decision was communicated through a Department of Health and Human Services (HHS) press release. It provides evidence-based recommendations on the use of vaccines for children and adults, informs decisions about insurance coverage, and helps determine eligibility for publicly funded programs such as Vaccines for Children (VFC).

article thumbnail

RFK Jr looks to alter rare disease regulation by fast-tracking drug approvals

Pharmaceutical Technology

The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SpliceBio secures $135m for gene therapy development

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.

article thumbnail

NHC Comments on Medicare Prescription Payment Plan

Putting Patients First Blog

The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.

article thumbnail

Clinical trials for rare diseases

European Pharmaceutical Review

How does the qualification package support more meaningful endpoints and rare disease research as a result? Because the submission of the plan will open this dialogue, it will also socialise these issues with other rare disease populations and provide the opportunity to mitigate them in their own communities.

article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.